Speaker illustration

Doctor John Maraganore

Cambridge ()

Dr. John Maraganore serves as the CEO and a Director of Alnylam, the company that translated Nobel-prize winning RNA interference (RNAi) into a whole new class of innovative medicines. Dr. Maraganore supports the industry at large, serving on the boards of directors for growing biotech companies like Agios Pharmaceuticals. He is a former chair of the Biotechnology Industry Organization (BIO) Board and member of the BIO Executive Committee. Before joining Alnylam, Dr. Maraganore served as Senior Vice President, Strategic Product Development for Millennium Pharmaceuticals, Inc. Prior to Millennium, Dr. Maraganore served as Director of Molecular Biology and Director of Market and Business Development at Biogen, Inc., where he invented and led the discovery and development of Angiomax™ (bivalirudin for injection, formerly Hirulog™) currently marketed by The Medicines Company. Dr. Maraganore received his M.S. and Ph.D. in biochemistry and molecular biology at the University of Chicago.

Silencing the messenger: RNAi therapeutics as a new class of innovative medicines.

Event: ESC Congress 2021 - The Digital Experience

Topic: Genetics, Epigenetics, ncRNA

Session: ESC Paul Hugenholtz Lecture for Innovation and William Harvey Lecture on Basic Science

Thumbnail

This platform is supported by

logo Novo Nordisk